Neuropeptide Y (NPY) is a 36-amino acid peptide neurotransmitter and hormone that plays diverse roles in the central and peripheral nervous systems. It is one of the most abundant neuropeptides in the mammalian brain and is critically involved in stress response, appetite regulation, energy homeostasis, and circadian rhythms. Emerging evidence links NPY signaling to neuroprotection and modulation of neurodegenerative processes in Alzheimer's Disease (AD), Parkinson's Disease (PD), and related conditions [1][2].
| Neuropeptide Y (NPY) |
|---|
| Protein Name | Neuropeptide Y |
| Gene | [NPY](/genes/npy) |
| UniProt ID | [P01308](https://www.uniprot.org/uniprot/P01308) |
| PDB Structures | [1RON](https://www.rcsb.org/structure/1RON), [1QFA](https://www.rcsb.org/structure/1QFA) |
| Molecular Weight | ~10,271 Da (mature peptide) |
| Subcellular Localization | Secreted peptide (dense-core vesicles) |
| Protein Family | Neuropeptide Y family (PP-fold) |
| Brain Regions | Hypothalamus, amygdala, [hippocampus](/brain-regions/hippocampus), [cortex](/brain-regions/cortex), striatum |
NPY is synthesized as a 97-amino acid precursor (pre-pro-NPY) that undergoes proteolytic processing:
- Pre-pro-NPY (97 aa): Signal peptide + NPY sequence
- Pro-NPY (69 aa): After signal peptide cleavage
- Mature NPY (36 aa): C-terminal amide, formed by peptidylglycine α-hydroxylating monooxygenase (PAM)
- PP-fold motif: NPY shares the pancreatic polypeptide fold with peptide YY (PYY) and pancreatic polypeptide (PP)
- N-terminal coil: Important for receptor binding specificity
- C-terminal tail: Essential for receptor activation
- Amidation: C-terminal Tyr36 is amidated, crucial for biological activity
NPY is expressed in various brain regions and performs multiple functions:
- Stress response: Modulates hypothalamic-pituitary-adrenal (HPA) axis activity
- Appetite regulation: Orexigenic (appetite-stimulating) effects via Y1 and Y5 receptors
- Energy homeostasis: Regulates energy balance and metabolism
- Circadian rhythms: Shows circadian secretion patterns
- Memory and learning: Influences hippocampal synaptic plasticity
- Anxiety and mood: Anxiolytic effects in the amygdala
- Seizure control: Endogenous anticonvulsant
NPY acts through five G protein-coupled receptors (GPCRs):
| Receptor |
Distribution |
Primary Effects |
| Y1R (NPY1R) |
Brain, periphery |
Anxiolysis, appetite, vasoconstriction |
| Y2R (NPY2R) |
Brain (presynaptic) |
Inhibits neurotransmitter release |
| Y4R (NPY4R) |
Peripheral tissues |
Energy homeostasis |
| Y5R (NPY5R) |
Hypothalamus |
Appetite regulation |
| Y6R (NPY6R) |
Limited (pseudogene in humans) |
N/A |
NPY alterations are implicated in AD pathophysiology:
- NPY levels: Variable reports—some studies show increased NPY in AD brains, others show decreased
- Y1R expression: Reduced Y1R binding in AD hippocampus
- Y2R alterations: Changes in Y2R in AD cortex
- Anti-excitotoxic effects: NPY protects against glutamate-induced neurotoxicity via Y2R
- Anti-amyloid effects: NPY may reduce amyloid-beta (Aβ) toxicity
- Memory enhancement: Y1R and Y5R activation improves memory consolidation
- Neurogenesis: NPY promotes hippocampal neurogenesis
- NPY receptor agonists as cognitive enhancers
- Y1R/Y5R-targeted AD therapeutics
- Gene therapy approaches using NPY overexpression
NPY interactions in PD include:
- Dopaminergic system: NPY modulates dopaminergic neuron survival
- Motor control: NPY in basal ganglia influences movement
- Levodopa-induced dyskinesia: Y1R antagonism may reduce dyskinesias
- Neuroinflammation: NPY exerts anti-inflammatory effects in microglial models
- NPY interneurons are relatively spared in HD
- NPY overexpression may provide neuroprotection
- Y2R agonists under investigation
- NPY is a potent endogenous anticonvulsant
- NPY gene therapy in clinical trials for epilepsy
- Seizures upregulate NPY expression
¶ Stroke and Ischemia
- NPY is neuroprotective in cerebral ischemia
- Y1R and Y5R mediate ischemic preconditioning
| Target |
Approach |
Status |
| Y1R agonists |
Cognitive enhancement |
Preclinical |
| Y2R agonists |
Anti-excitotoxic |
Preclinical |
| Y5R antagonists |
Appetite suppression |
Clinical (obesity) |
| NPY gene therapy |
Epilepsy treatment |
Phase I/II trials |
- Blood-brain barrier penetration
- Receptor subtype selectivity
- Balancing anxiogenic vs anxiolytic effects
- Dose-dependent effects
- Cerda-Reverter JM, et al. Neuropeptide Y gene and receptors: evolutionary aspects. Prog Brain Res. 2011
- Colmers WF, Bleakman D. Effects of neuropeptide Y on neuronal excitability. Neuropeptides. 2004
- Sørensen G, et al. NPY and neuroprotection. Prog Neuropsychopharmacol Biol Psychiatry. 2021
- Redrobe JP, et al. NPY Y1 receptors in Alzheimer's disease. J Neurochem. 2002
- Grove KL, et al. NPY in the developing brain. J Comp Neurol. 2001